These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21474126)

  • 21. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human chorionic gonadotropin vs. gonadotropin-releasing hormone agonist trigger in assisted reproductive technology--"the king is dead, long live the king!".
    Humaidan P; Polyzos NP
    Fertil Steril; 2014 Aug; 102(2):339-41. PubMed ID: 24907915
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.
    Gómez-Palomares JL; Acevedo-Martín B; Chávez M; Manzanares M; Ricciarelli E; Hernández ER
    Fertil Steril; 2008 Mar; 89(3):620-4. PubMed ID: 17678911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Priming with progestin, but not GnRH antagonist, induces a consistent endocrine response to exogenous gonadotropins in induced and spontaneously ovulating cats.
    Pelican KM; Wildt DE; Ottinger MA; Howard J
    Domest Anim Endocrinol; 2008 Feb; 34(2):160-75. PubMed ID: 17369001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors.
    Martínez F; Clua E; Santmartí P; Boada M; Rodriguez I; Coroleu B
    Fertil Steril; 2010 Nov; 94(6):2433-6. PubMed ID: 20430379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.
    Koichi K; Yukiko N; Shima K; Sachiko S
    J Assist Reprod Genet; 2006 May; 23(5):223-8. PubMed ID: 16786420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
    Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preimplantation embryo development and serum steroid levels in immature rats induced to ovulate or superovulate with pregnant mares' serum gonadotropin injection or follicle-stimulating hormone infusions.
    Leveille MC; Armstrong DT
    Gamete Res; 1989 May; 23(1):127-38. PubMed ID: 2501205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superovulation alters embryonic poly(A)-binding protein (Epab) and poly(A)-binding protein, cytoplasmic 1 (Pabpc1) gene expression in mouse oocytes and early embryos.
    Ozturk S; Yaba-Ucar A; Sozen B; Mutlu D; Demir N
    Reprod Fertil Dev; 2016 Mar; 28(3):375-83. PubMed ID: 25034140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Kalogeropoulou L; Papanikolaou E; Tarlatzis BC
    Fertil Steril; 2011 Feb; 95(2):558-62. PubMed ID: 20637457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer.
    Devroey P; Pellicer A; Nyboe Andersen A; Arce JC;
    Fertil Steril; 2012 Mar; 97(3):561-71. PubMed ID: 22244781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of gonadotropin-releasing hormone antagonists in in vitro fertilization.
    Diedrich K; Ludwig M; Felberbaum RE
    Semin Reprod Med; 2001 Sep; 19(3):213-20. PubMed ID: 11679902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.